openPR Logo
Press release

AnaptysBio, Inc. (NASDAQ: ANAB) Long Term Investor Alert: Investigation of potential Wrongdoing

07-06-2020 06:14 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares.

An investigation on behalf of current long term investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares.

An investigation on behalf of current long-term investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) concerning potential breaches of fiduciary duties by certain directors and officers of AnaptysBio, Inc was announced.

Investors who are current long term investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ANAB stocks follows a lawsuit filed against AnaptysBio, Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ANAB stocks, concerns whether certain AnaptysBio directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that the defendants made false and misleading statements regarding the purported efficacy of etokimab, touting data from the Company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication, that in truth, the Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were, and that as a result of Defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices between October 10, 2017 and November 7, 2019.

Those who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AnaptysBio, Inc. (NASDAQ: ANAB) Long Term Investor Alert: Investigation of potential Wrongdoing here

News-ID: 2085505 • Views: 500

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for AnaptysBio

Allergy Therapeutics - Pipeline Analysis 2018 | AnaptysBio, HAL Allergy Group, A …
Allergy is an immune system response, that can range from mild to severe life-threatening reactions. The substances that can cause an allergy are known as allergens. Some common allergens include pollen, dust, insect stings, medications, mold spores, latex, and animal dander. Download the sample report @ https://www.pharmaproff.com/request-sample/1045 Allergy triggers the release of inflammatory mediators such as interleukins, serotonin, cytokines, and prostaglandins, which can produce several systemic physiological reactions like mucous secretion and
Transplant Complications Drug Development Pipeline Review 2018 - AbbVie, AbGenom …
Transplant Complications Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products. GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves
Peanut Allergy Therapeutics Pipeline - Key Players Analysis Aimmune Therapeutics …
Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately
Dermatology Drugs Market By Growth Factors and Key Players: Allergan Plc, Valean …
The Future of Dermatology Drugs Market: Novel Treatments and Increased Diagnosis in Psoriasis and Atopic Dermatitis Drives Market Growth “Dermatology Drugs Market by Therapeutic Area Segments (Atopic Dermatitis, Psoriasis, Acne, Rosacea), Acne Drug Types (Doxycycline, Absorica, Clindamycin, Myorisan, Aczone, Epiduo) Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), by Approves Treatments (Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Golimumab (Simponi), Brodalumab (Siliq), Guselkamab (Tremfya) and Others) and
Dermatology Drugs Market Key Player Analysis - Allergan Plc, Valeant Pharmaceuti …
Polaris Market Research presents a most up-to-date research on “Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022”. Polaris Market Research assumes that with the expected launch of the
Antibody Library Technologies Market Innovation, Industry Technology, Size, Shar …
Antibody Library Technologies Market including size, forecast, trend, share, growth, overview, key players, technologies, market drivers, challenges, standardization, regulatory landscape, opportunities, future roadmap, value chain, ecosystem player profiles and strategies forecast to 2025. For Sample Copy of this Report at – https://www.orianresearch.com/request-sample/650759 The global market is witnessing reasonably higher growth due to increase in technological advancements as well as rising geriatric population. Rising number of surgical procedures, increasing rate of diagnosis and